Abstract
. The same year, we demonstrated (1) that tau in AD brain was abnormally hyperphosphorylated and, in this state, was polymerized into paired helical filaments (PHF)/neurofibrillary tangles [5] , and (2) that, unlike normal tau, cytosolic abnormally hyperphosphorylated tau in AD brain was unable to promote microtubule assembly [6] . [7] and alternate splicing of its pre-mRNA, generating different isoforms in bovine brain [8] discovered by Kirschner's lab; (ii ) the presence of six molecular isoforms of tau by alternate splicing in the human brain by Goedert et al. [9] ; (iii ) the identification of the cyclin-dependent protein kinase 5 (cdk5) and glycogen synthase kinase-3 (GSK-3) as the major tau kinase activities that can abnormally hyperphosphorylate tau by Imahori's group [10] [11] [12] ; (iv ) the mapping of the phosphorylation sites of normal [13] and PHF tau [73] , and ubiquitination of PHF tau [14] 
These findings laid down the foundation of very exciting studies on the molecular mechanisms of AD and molecular biomarkers associated with plaques and tangles, and development of disease modifying drugs. Key findings on tau include (i ) the cloning of tau gene from mouse brain

by Ihara's lab; (v ) the identification of Ser262 as one of the major functional phosphorylation sites of tau and its phosphorylation by microtubule-affinity regulation kinase (MARK) by
Mandelkow's lab [15, 16] ; (vi ) the higher-than-normal adult level of phosphorylation in foetal tau by the group of Lee and Trojanowski [17] ; (vii ) [39] [40] [41] . These mutated taus and the 4-repeat tau become more favourable substrates for abnormal hyperphosphorylation [42] .
Etiopathogenesis
Currently, the most popular hypothesis on the etiopathogenesis of AD is the Amyloid Cascade Hypothesis, according to which the generation of A␤ is the primary pathological event which leads to neurofibrillary degeneration and dementia [43, 44] . Consistent with this hypothesis, both intracerebral infusion of A␤ in FTDP-17 tau mutation P301L-expressing transgenic mice, as well as crossing these animals with APPTg2576 (APP Swedish plus London mutations), were found to exacerbate neurofibrillary pathology [45, 46] and, in the triple transgenic mice 3XTgAD (APPSWE-PS1M146V-tau P301L), ␤-amyloid deposition was found to precede the neurofibrillary pathology and these animals showed more neurofibrillary pathology than the double transgenic Tg2X mice [47, 48] [52] [53] [54] and truncation of tau [55] [56] [57] have been reported in AD, the most established and the most compelling cause of dysfunctional tau in AD and related tauopathies is the abnormal hyperphosphorylation of this protein [5, 6, 23] . Tau, a phosphoprotein which normally contains 2-3 mol. of phosphate/mol. of the protein [58] , is abnormally hyperphosphorylated in AD brain [6] and, in this state, is the major protein subunit of the paired helical filaments/neurofibrillary tangles [4, 5, 59, 60] . Two major known functions of tau are its ability to promote assembly and to maintain structure of microtubules [61] . These functions of tau are regulated by its degree of phosphorylation [23, [62] [63] [64] . In AD brain there is as much normal tau as in agematched control human brain, but, in addition, the diseased brain contains 4-8-fold of abnormally hyperphosphorylated tau [65, 66] . As much as 40% of the abnormally hyperphosphorylated tau is present in the cytosol and not polymerized into paired helical filaments/neurofibrillary tangles [58] . [63, 64, 67] . In contrast, the AD cytosolic abnormally hyperphosphorylated tau (AD P-tau) not only is unable to bind to tubulin and promote microtubule assembly, but also inhibits assembly and disrupts microtubules [23, 68] . [23, [68] [69] [70] [71] . Furthermore, in vitro dephosphorylation of neurofibrillary tangles disaggregates filaments and, as a result, the tau released behaves like normal protein in promoting microtubule assembly [70] . Thus, two characteristics of AD abnormally hyperphosphorylated tau are (1) 
The tau polymerized into neurofibrillary tangles is apparently inert and neither binds to tubulin nor promotes its assembly into microtubules
This toxic property of the pathological tau involves the sequestration of normal tau by the diseased protein [22, 23]. The AD P-tau also sequesters the other two major neuronal microtubule associated proteins MAP1 A/B and MAP2 [23]. This toxic behavior of the AD P-tau appears to be solely due to its abnormal hyperphosphorylation because dephosphorylation of diseased tau converts it into a normal-like protein
Signal transduction pathways involved Tau kinases
The state of phosphorylation of a phosphoprotein is a function of the balance between the activities of the protein kinases and the PPs that regulate its phosphorylation. Tau, which is phosphorylated at over 38 serine/threonine residues in AD [73, 74] , is a substrate for several protein kinases [75, 76] [77, 78] . A large number of the abnormally hyperphosphorylated sites in tau are proline-directed, that is serine/threonine followed by proline which are canonical sites of proline-directed protein kinases (PDPKs).
. Among these kinases, GSK-3, cyclin dependent protein kinase-5 (cdk5), casein kinase-1 (CK-1), protein kinase A (PKA), calcium and calmodulin-dependent protein kinase-II (CaMKII), casein kinase-1 (CK-1), MAP kinase ERK 1/2 and stress-activated protein kinases have been most implicated in the abnormal hyperphosphorylation of tau
GSK-3␤ and cdk5 phosphorylate tau at a large number of sites, most of which are common to the two enzymes [79, 80] . The expressions of GSK-3␤ and cdk5 are high in the brain [81] [82] [83] and both enzymes have been shown to be associated with all stages of neurofibrillary pathology in AD [84, 85] . [86] [87] [88] [89] [90] [91] [92] [93] .
Overexpression of GSK-3␤ in cultured cells and in transgenic mice results in hyperphosphorylation of tau at several of the same sites seen in AD and inhibition of this enzyme by lithium chloride attenuates phosphorylation in these models
Cdk5 requires for its activity interaction with p39 or p35 or, better, their proteolytic products p29 or p25, respectively, which are generated in post mitotic neurons by digestion with calpains [94, 95] . Overexpression of p25 in transgenic mice, which results in an increase in the activity of this enzyme, also produces hyperphosphorylation of tau [96, 97] . [79, [110] [111] [112] . The priming of tau by PKA appears to be sufficient to promote the abnormal hyperphosphorylation of tau by the basal level of GSK-3␤ activity in normal adult rat brain and leads to an impairment of spatial memory in these animals [113] . Although 
Tau phosphatases
The activities of PP-2A and PP-1 are compromised by ~ 20% in AD brain [19, 114] [107] , PKA [117, 118] , MAP kinase kinase (MEK1/2), extracellular regulated kinase (ERK 1/2) and P70S6 kinase [78, 102] 
Role of decreased brain glucose metabolism in neurofibrillary degeneration
In addition to abnormal hyperphosphorylation, tau is also abnormally glycosylated and the latter appears to precede the former in AD brain [136, 137] . In vitro studies indicate that the abnormal glycosylation promotes tau phosphorylation with PKA, GSK-3␤ and ckd5, and inhibits dephosphorylation of tau with PP2A and PP5 [138, 139] . In addition, like some other neuronal phosphoproteins, tau is also O-GlcNAcylated [140, 141] [144] . AD [117] , and that this effect of the drug was through disinhibition of PP-2A activity [156] which we previously showed to be down regulated in AD brain [19] . Based on our finding on the restoration of the PP-2A activity by memantine, Gunnarrsson et al. [157] [135] suggest that compounds which inhibit both GSK-3 and cdk5 might even be more effective than the highly selective inhibitors of one of these enzymes in inhibiting neurofibrillary degeneration.
. In contrast to classical N-or O-glycosylation, O-GlcNAcylation which involves the addition of a single sugar at serine/threonine residues of a protein, dynamically post-translationally modifies cytoplasmic and nuclear proteins in a manner analogous to protein phosphorylation [142]. O-GlcNAcylation and phosphorylation reciprocally regulate each other. In AD, probably due to impaired glucose uptake/metabolism, there is a global decrease in O-GlcNAcylation, including that of tau. Decreased glucose metabolism in cultured cells and in mice, which decreases the O-GlcNAcylation of tau, produces abnormal hyperphosphorylation of this protein [143]. Thus, inhibition of O-GlcNAcylase, the enzyme which hydrolyses the removal of this sugar moiety from proteins, is a promising therapeutic target for AD and related tauopathies. Inhibition of O-GlcNAcylase with PUGNac or NAG-AE inhibits hyperphosphorylation of tau by increasing its O-GlcNAcylation.
Subgroups of AD
Given the multi-factorial nature of AD, identification of different disease subgroups which might represent different etiopathogenic mechanisms will not only improve the accuracy of the diagnosis but also help develop and measure the efficacy of different therapeutic drugs towards these disease subgroups. Because of clinical heterogeneity, the diagnosis of AD remains probable till postmortem histopathological examination, and is made primarily by exclusion of other causes of dementia
Memantine, a low to moderate affinity NMDA receptor antagonist, which improves mental function and the quality of daily living of patients with moderate to severe AD [158, 159] , restores the PP-2A activity, and reduces the abnormal hyperphosphorylation of tau at Ser-262 and the associated neurodegeneration in hippocampal slice cultures from adult rats, and PC-12 cells in culture [117, 156] . Furthermore [156] . The CSF level of phosphotau is significantly reduced in AD patients after one year treatment with memantine [157] . All these findings taken together suggest that PP-2A is a promising therapeutic target for AD and related tauopathies.
Recent studies suggest inhibition of calpains as another approach for the inhibition of neurofibrillary degeneration [160] . Calpain, the activity of which is up-regulated in AD brain, activates cdk5 through cleavage of its activators p39 and p35 to p29 and p25, respectively [94, 95] . Calpain also cleaves and activates calcineurin, which regulates the phosphorylation of CREB [160] . Thus [161, 162] . Most recently, immunization of P301L transgenic mice with a small tau phosphopeptide has been reported to clear the hyperphosphorylated tau [163] . Another approach to overcome the inhibitory activity of the hyperphosphorylated tau is the use of microtubule stabilizing drugs like taxol [118, 162, 164] .
A 
